AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1516602 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg b.d. for 30 days
Number of subjects: 22
Study 1516602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6408669 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150‐350 mg/day)
Number of subjects: 40
Study 31792291 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbolus technique (MBT)
Number of subjects: 70
Study 31792291 — intervention group
Group type: COMPARATOR
Intervention: Standard CTA protocol
Number of subjects: 70
Study 31792291 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bolus delay protocol
Number of subjects: 70
Study 30001195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of extra-amniotic Foley's catheter inflated by 30 cm3 of normal saline and 25 micrograms of vaginal misoprostol
Number of subjects: 180
Study 30001195 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol alone (25 micrograms)
Number of subjects: 180
Study 30001195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of extra-amniotic Foley's catheter and vaginal misoprostol
Number of subjects: 180
Study 30001195 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 180
Study 27825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) program (two 90-min lessons with a 1-week interval)
Number of subjects: 37
Study 24845183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (1 °C) during SECPT
Number of subjects: 61
Study 24845183 — intervention group
Group type: COMPARATOR
Intervention: Room temperature water immersion (20 °C) during SECPT
Number of subjects: 61
Study 22677755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (antioxidant)
Number of subjects: 98
Study 20164320 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 20-40 g in 300 mL water
Number of subjects: 0
Study 20164320 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 10-40 g in 300 mL water
Number of subjects: 0
Study 20164320 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein Hydrolysate (WPH) 10 g in 300 mL water
Number of subjects: 0
Study 20164320 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) > or = 10 g
Number of subjects: 0
Study 20164320 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein Hydrolysate (WPH) 10 g
Number of subjects: 0
Study 18029338 — intervention group
Group type: EXPERIMENTAL
Intervention: NeOpuntia
Number of subjects: 68
Study 18029338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16007036 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 16007036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12525910 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and marsupialization technique (Group 1, n=20)
Number of subjects: 40
Study 12525910 — intervention group
Group type: COMPARATOR
Intervention: Sinus excision technique (Group 2, n=20)
Number of subjects: 40
Study 9797756 — intervention group
Group type: EXPERIMENTAL
Intervention: Air during exercise
Number of subjects: 20
Study 9797756 — intervention group
Group type: COMPARATOR
Intervention: 35% oxygen during exercise
Number of subjects: 20
Study 9797756 — intervention group
Group type: COMPARATOR
Intervention: Induced hypoxaemia at rest (titrated mixture of air and oxygen)
Number of subjects: 20
Study 7659385 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-BMIPP
Number of subjects: 9
Study 7659385 — intervention group
Group type: COMPARATOR
Intervention: 201Tl
Number of subjects: 9
Study 7659385 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP
Number of subjects: 9
Study 2799651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm cefazolin intramuscularly before surgery
Number of subjects: 0
Study 2799651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm cefazolin in buttock fat, buttock muscle, or by intravenous injection
Number of subjects: 0
Study 2799651 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm cefazolin intravenously
Number of subjects: 0
Study 2799651 — intervention group
Group type: COMPARATOR
Intervention: 1 gm cefazolin intravenously
Number of subjects: 0
Study 1095040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg diazepam
Number of subjects: 34
Study 1095040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg diazepam
Number of subjects: 34
Study 1095040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg diazepam
Number of subjects: 34
Study 31952882 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 831
Study 30698272 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM zolmitriptan 3.8 mg
Number of subjects: 321
Study 25605856 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 636
Study 25605856 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 636
Study 23371540 — intervention group
Group type: EXPERIMENTAL
Intervention: LipoNasal (LN)
Number of subjects: 92
Study 23371540 — intervention group
Group type: COMPARATOR
Intervention: Bepanthen (BP)
Number of subjects: 92
Study 23371540 — intervention group
Group type: COMPARATOR
Intervention: Rhinomer (RH)
Number of subjects: 92
Study 21749017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 845
Study 21749017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study 19808140 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion
Number of subjects: 13
Study 19808140 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion in patients receiving hemodialysis
Number of subjects: 13
Study 16623314 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person progress reports from the surgical liaison nurse (SLN)
Number of subjects: 92
Study 16623314 — intervention group
Group type: COMPARATOR
Intervention: Routine perioperative care
Number of subjects: 92
Study 10579246 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 160
Study 10579246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 8678170 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up assessments at 6, 12, and 18 months
Number of subjects: 188
Study 1763796 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of vaccine
Number of subjects: 30
Study 1763796 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 30
Study 1763796 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of vaccine
Number of subjects: 30
Study 1763796 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of vaccine
Number of subjects: 30
Study 1763796 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 6130077 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30, 60, and 90 mg)
Number of subjects: 8
Study 6130077 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyl-p-tyrosine and gamma-butyrolactone
Number of subjects: 8
Study 6130077 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 8
Study 31289192 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child depression symptoms
Number of subjects: 223
Study 31289192 — intervention group
Group type: EXPERIMENTAL
Intervention: Family chaos
Number of subjects: 223
Study 31289192 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional triggers of asthma
Number of subjects: 223
Study 29231094 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily after 5 days of low-molecular-weight heparin)
Number of subjects: 1050
Study 29231094 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg once daily for 1 month followed by 150 IU/kg once daily)
Number of subjects: 1050
Study 29231094 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1050
Study 29231094 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1050
Study 27294991 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based intervention (n = 98)
Number of subjects: 217
Study 27294991 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group, n = 119)
Number of subjects: 217
Study 24562789 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (cohort I)
Number of subjects: 0
Study 24562789 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (cohort II)
Number of subjects: 0
Study 24562789 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution-based analysis (cohort I)
Number of subjects: 0
Study 24562789 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution-based analysis (cohort II)
Number of subjects: 0
Study 23197976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitor (vildagliptin)
Number of subjects: 0
Study 23197976 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 20206803 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR using the Talent eLPS stent graft
Number of subjects: 166
Study 20206803 — intervention group
Group type: COMPARATOR
Intervention: Open surgical AAA repair
Number of subjects: 166
Study 20206803 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR using the Talent eLPS stent graft (5-year follow-up)
Number of subjects: 166
Study 20206803 — intervention group
Group type: EXPERIMENTAL
Intervention: CoilTrac delivery system (confirmatory group)
Number of subjects: 166
Study 16806875 — intervention group
Group type: EXPERIMENTAL
Intervention: daily rhDNase
Number of subjects: 0
Study 16806875 — intervention group
Group type: EXPERIMENTAL
Intervention: alternate day rhDNase
Number of subjects: 0
Study 16806875 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline
Number of subjects: 0
Study 16806875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16223001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 276
Study 16223001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 276
Study 12084804 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT once/week
Number of subjects: 45
Study 12084804 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT three times/week
Number of subjects: 45
Study 12084804 — intervention group
Group type: COMPARATOR
Intervention: No AAT
Number of subjects: 45
Study 9871843 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (0.4 mg intravenous bolus)
Number of subjects: 9
Study 9871843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8714022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous administration of oxytocin (OT)
Number of subjects: 106
Study 8714022 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous administration of oxytocin (OT)
Number of subjects: 106
Study 2398244 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulphate (STS)
Number of subjects: 52
Study 2398244 — intervention group
Group type: COMPARATOR
Intervention: absolute alcohol (AA)
Number of subjects: 52
Study 30947936 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2754
Study 30947936 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 2754
Study 28625615 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 105
Study 28625615 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 105
Study 28625615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 28625615 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 105
Study 27997954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Language Action Therapy (ILAT)
Number of subjects: 24
Study 27997954 — intervention group
Group type: COMPARATOR
Intervention: Promoting Aphasic Communicative Effectiveness (PACE)
Number of subjects: 24
Study 24389597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20mg/day) for 30 days
Number of subjects: 155
Study 24389597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4mg/day) for 30 days
Number of subjects: 155
Study 22353460 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare for Kids (SFK) A (low amplitude, 7°)
Number of subjects: 68
Study 22353460 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare for Kids (SFK) B (high amplitude, 9°)
Number of subjects: 68
Study 22353460 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Stages 3 toothbrush (MTB)
Number of subjects: 68
Study 20521319 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 32
Study 20521319 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32
Study 20521319 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 32
Study 17955096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 1175
Study 17955096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine with concomitant antipsychotics
Number of subjects: 1175
Study 17955096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine with concomitant valproate, lithium, or antidepressants
Number of subjects: 1175
Study 16274805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nose ointment
Number of subjects: 33
Study 16274805 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study 12110024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified cellulose membrane (CL-E)
Number of subjects: 8
Study 12110024 — intervention group
Group type: COMPARATOR
Intervention: Low-flux cellulose acetate (CA)
Number of subjects: 8
Study 10542930 — intervention group
Group type: EXPERIMENTAL
Intervention: At risk group (men with hyperlipidaemia)
Number of subjects: 197
Study 10542930 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients undergoing nasal surgery)
Number of subjects: 197
Study 10542930 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with fasting lipids > 6.5 mmol/l
Number of subjects: 197
Study 8998247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4736
Study 8998247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 4736
Study 8998247 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 4736
Study 1699888 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 0.33% bupivacaine (20 ml 0.5% bupivacaine + 10 ml of N saline)
Number of subjects: 84
Study 1699888 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of 0.5% bupivacaine + 10 ml of dextraven-150 (6% solution in 5% dextrose)
Number of subjects: 84
Study 356237 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (900 mg daily for 3 weeks)
Number of subjects: 39
Study 356237 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg daily for 3 weeks)
Number of subjects: 39
Study 31987456 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label recommendations supported by randomized controlled trial (RCT) data
Number of subjects: 44
Study 31987456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanism-based agents applied in rare cancers
Number of subjects: 44
Study 31987456 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-RCT data showing significant efficacy
Number of subjects: 44
Study 31987456 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations without RCT data
Number of subjects: 44
Study 31987456 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN recommendations
Number of subjects: 44
Study 29072830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 1060
Study 29072830 — intervention group
Group type: COMPARATOR
Intervention: Control (no provision of kit)
Number of subjects: 1060
Study 25760065 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied once per week until remission of pain (T1)
Number of subjects: 17
Study 25760065 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied once per week followed immediately by restoration with resin composite (T2)
Number of subjects: 17
Study 25760065 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel once per week until remission of pain and then restoration with resin composite (T3)
Number of subjects: 17
Study 25760065 — intervention group
Group type: COMPARATOR
Intervention: Restoration with resin composite (T4)
Number of subjects: 17
Study 23538621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 20
Study 23538621 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 22338171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX) at 10 mg plus low-dose methylprednisolone (MP) at 0.5 mg x kg(‐1) x d(‐1) in Group A
Number of subjects: 78
Study 22338171 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methylprednisolone (MP) at 1-2 mg x kg(‐1) x d(‐1) in Group B
Number of subjects: 78
Study 19570931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57
Study 19570931 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 57
Study 19570931 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 17705571 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10-20 mg once daily
Number of subjects: 195
Study 17705571 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 195
Study 15385735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/d for 30 days)
Number of subjects: 217
Study 15385735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 11216728 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic (warm) conditions during CABS
Number of subjects: 209
Study 11216728 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic (cold) conditions during CABS
Number of subjects: 209
Study 9300226 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 20
Study 9300226 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 20
Study 7936281 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 4
Study 7936281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 3612823 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbach's preorgasmic treatment program
Number of subjects: 11
Study 3612823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 29244528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Number of subjects: 355
Study 29244528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + Aromatase Inhibitor (AI)
Number of subjects: 355
Study 29244528 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Number of subjects: 355
Study 29244528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + TRAS + AI
Number of subjects: 355
Study 28479001 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg 3 times a day
Number of subjects: 332
Study 28479001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg 3 times a day
Number of subjects: 332
Study 28479001 — intervention group
Group type: COMPARATOR
Intervention: Combined AMS incidence
Number of subjects: 332
Study 26630680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐methylenetetrahydrofolate (1 mg daily)
Number of subjects: 220
Study 26630680 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (1 mg daily)
Number of subjects: 220
Study 24270304 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 226
Study 24270304 — intervention group
Group type: COMPARATOR
Intervention: Printed brochure training
Number of subjects: 226
Study 24270304 — intervention group
Group type: COMPARATOR
Intervention: Computer-based training
Number of subjects: 226
Study 20950507 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs (face-to-face and self-directed packages)
Number of subjects: 342
Study 20950507 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for RCF staff (30-minute blocks, flexible program)
Number of subjects: 342
Study 18925903 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA/Aza
Number of subjects: 52
Study 18925903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac/MMF
Number of subjects: 52
Study 18925903 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 17159119 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraxia treatment
Number of subjects: 33
Study 17159119 — intervention group
Group type: COMPARATOR
Intervention: Control (aphasia) treatment
Number of subjects: 33
Study 15504842 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/RTV) at 667/100 mg every 12 hours
Number of subjects: 27
Study 15504842 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (IDV) alone at 800 mg every 8 hours
Number of subjects: 27
Study 11174287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal administration of peppermint oil (200 mL solution: 8 mL peppermint oil + 0.2 mL Tween 80 per 1 L water with 0.04% indigo carmine)
Number of subjects: 409
Study 11174287 — intervention group
Group type: COMPARATOR
Intervention: Control group (solution without peppermint oil)
Number of subjects: 409
Study 9430090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sitosterol intake increased to 1.8 mg/kg, 2.6 mg/kg, and 3.5 mg/kg/day in the homozygote after a basal low-sitosterol diet (33 mg per 2000 kcal).
Number of subjects: 3